title: 68Ga-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients.
abstract: We evaluated the clinical utility of 68Ga-PSMA-11 PET/CT for staging and risk stratification of treatment-naïve prostate cancer (PCa) and metastatic castrate-resistant prostate cancer (mCRPC). Twenty-two consecutive patients with treatment-naïve PCa and 18 with mCRPC were enrolled. 68Ga-PSMA-11 PET/CT and magnetic resonance imaging (MRI) were performed for the evaluation of primary prostatic lesions, and bone scans were used for evaluation bone metastasis. Among the 40 patients, 37 (92.5% [22 treatment-naïve PCa, 15 mCRPC]) showed PSMA-avid lesions on 68Ga-PSMA-11 images. Only 3 patients with stable mCRPC after chemotherapy were negative for PSMA. The sensitivity, specificity and accuracy of 68Ga-PSMA-11 imaging were 97.3%, 100.0% and 97.5%, respectively. The maximum standardized uptake (SUVmax) of prostatic lesions was 17.09 ± 11.08 and 13.33 ± 12.31 in treatment-naïve PCa and mCRPC, respectively. 68Ga-PSMA-11 revealed 105 metastatic lymph nodes in 15 patients; the SUVmax was 16.85 ± 9.70 and 7.54 ± 5.20 in treatment-naïve PCa and mCRPC, respectively. 68Ga-PSMA-11 PET/CT also newly detected visceral metastasis in 9 patients (22.5%) and bone metastasis in 29 patients (72.5%). 68Ga-PSMA-11 PET/CT exhibits potential for staging and risk stratification in naïve PCa, as well as improved sensitivity for detection of lymph node and remote metastasis.
authors.affiliation: Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.
authors.forename: Shiming
authors.initials: S
authors.lastname: Zang
authors.affiliation: Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.
authors.forename: Guoqiang
authors.initials: G
authors.lastname: Shao
authors.affiliation: Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.
authors.forename: Can
authors.initials: C
authors.lastname: Cui
authors.affiliation: Department of Nuclear Medicine, PET Centre, No. 1 Hospital Affiliated to Nanjing Medical University, Nanjing 210029, China.
authors.forename: Tian-Nv
authors.initials: TN
authors.lastname: Li
authors.affiliation: Department of Pathology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.
authors.forename: Yue
authors.initials: Y
authors.lastname: Huang
authors.affiliation: Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.
authors.forename: Xiaochen
authors.initials: X
authors.lastname: Yao
authors.affiliation: Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.
authors.forename: Qiu
authors.initials: Q
authors.lastname: Fan
authors.affiliation: Department of Nuclear Medicine, The Affiliated Jiangyin Hospital of Southeast University Medical College, Jiangyin 214400, China.
authors.forename: Zejun
authors.initials: Z
authors.lastname: Chen
authors.affiliation: Department of Technology Development, China Isotope Radiation Corporation, No. 1 Nansixiang, Sanlihe, West District, Beijing 100045, China.
authors.forename: Jin
authors.initials: J
authors.lastname: Du
authors.affiliation: Department of Urology, Nanjing Medical University, Nanjing 210006, China.
authors.forename: Ruipeng
authors.initials: R
authors.lastname: Jia
authors.affiliation: Department of Urology, Nanjing Medical University, Nanjing 210006, China.
authors.forename: Hongbin
authors.initials: H
authors.lastname: Sun
authors.affiliation: The State Key Laboratory of Pharmaceutical Biotechnology, Department of Biochemistry, College of Life Sciences, Nanjing University, Nanjing 210006, China.
authors.forename: Zichun
authors.initials: Z
authors.lastname: Hua
authors.affiliation: Department of Nuclear Medicine, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China.
authors.forename: Jun
authors.initials: J
authors.lastname: Tang
authors.affiliation: Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.
authors.forename: Feng
authors.initials: F
authors.lastname: Wang
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D044466:Asian People; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000208:ethnology / Q000556:secondary; D002681:China; D004492:Edetic Acid / Q000031:analogs & derivatives; D005709:Gallium Isotopes; D005710:Gallium Radioisotopes; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging / Q000379:methods*; D009842:Oligopeptides; D009942:Organometallic Compounds; D000072078:Positron Emission Tomography Computed Tomography / Q000379:methods*; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging* / Q000208:ethnology; D064129:Prostatic Neoplasms, Castration-Resistant / Q000000981:diagnostic imaging* / Q000208:ethnology; D015203:Reproducibility of Results; D012307:Risk Factors; D012680:Sensitivity and Specificity
chemical_list: D005709:Gallium Isotopes; D005710:Gallium Radioisotopes; D009842:Oligopeptides; D009942:Organometallic Compounds; C000718244:gallium 68 PSMA-11; D004492:Edetic Acid
keywords: metastatic castrate-resistant prostate cancer; prostate-specific membrane antigen; risk stratification; staging; treatment-naïve prostate cancer